A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
X. Miao, Y. Luo, X. Huang, S. M. Y. Lee, Z. Yuan, Y. Tang, L. Chen, C. Wang, W. Jiang, W. Gao, X. Song, Y. Yan, T. Pang, Y. Zou, W. Fu, , Y. Xu
The paper develops a biparatopic antibody-ACE2 fusion (89C8-ACE2) that effectively blocks SARS-CoV-2 infection in vitro and neutralizes authentic virus at low nanomolar concentrations.
bioRxiv · Jun 14, 2020Immunology